A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Sponsor:

Sumitomo Dainippon Pharma Oncology, Inc.

Sponsor Study ID:

DSP-5336-101

CTO #:

103779

NCT Number:

NCT04988555

Phase:

I/II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Myeloid and Monocytic Leukemia

Study Objectives:

A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)